REFERENCES
- Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89(3)739–755, [INFOTRIEVE], [CSA]
- Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of β-thalassemia major in North America. Blood 2004; 104(1)34–39, [INFOTRIEVE], [CROSSREF], [CSA]
- Hoffbrand AV, Al-Refaie FN, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, Prescott E, Wonke B. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91(1)295–300, [INFOTRIEVE], [CSA]
- Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339(7)417–423, [INFOTRIEVE], [CROSSREF], [CSA]
- Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, Mangiagli A, Quarta G, Rizzo M, D'Ascola DG, Rozzo A, Midiri M. Deferiprone versus desferrioxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28(2)196–208, [INFOTRIEVE], [CROSSREF], [CSA]
- Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002; 360(9332)516–520, [INFOTRIEVE], [CROSSREF], [CSA]
- Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102(5)1583–1587, [INFOTRIEVE], [CROSSREF], [CSA]
- Mourad FH, Hoffbrand AV, Sheikh-Taha M. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003; 121(1)187–189, [INFOTRIEVE], [CROSSREF], [CSA]
- Chan YL, Li CK, Lam CW, Yu SC, Chik KW, To KF, Yeung DK, Howard R, Yuen PM. Liver iron estimation in β-thalassemia: comparison of MRI biochemical assay and histological grading. Clin Radiol 2001; 56(11)911–916, [INFOTRIEVE], [CROSSREF], [CSA]
- Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1(5)431–435, [INFOTRIEVE], [CSA]
- Tondury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol 1998; 101(3)413–415, [INFOTRIEVE], [CROSSREF], [CSA]
- Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini MR, Schwartz E, Cohen AR. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent β-thalassemia. Blood 2002; 100(5)1566–1569, [INFOTRIEVE], [CROSSREF], [CSA]